Vaginal Estrogen Use Nearly Tripled. Here's the Symptom Almost Nobody Names.

Of all the ways hormone therapy prescribing changed between 2017 and 2026, the sharpest shift wasn’t in who was prescribed it or how much — it was in where it went. Vaginal estrogen use nearly tripled, growing faster than oral tablets and second only to transdermal patches and gels. It is treating a set of symptoms that women bring up with almost nobody: not their friends, not their partners, and — more than any other perimenopause complaint — not their doctor.

Vaginal dryness, burning, discomfort during sex, and a cluster of urinary symptoms that get written off as “just something that happens” are collectively known in clinical terms as genitourinary syndrome of menopause, or GSM. It’s one of the few perimenopause symptoms with a genuinely effective, well-studied, low-risk treatment sitting right there — and it is also one of the most undertreated conditions in the entire menopause transition, for reasons that have almost nothing to do with whether the treatment works.

This article covers what actually happened in the prescribing data, what GSM is and why it starts earlier and lasts longer than most people expect, why so many women never raise it, and what the evidence actually says about the options — hormonal and not.

---

What the Data Actually Shows

The figures come from the same Epic Research Cosmos analysis behind the broader HRT prescribing surge already covered on this site — 163 million adult women seen in US outpatient care between January 2017 and April 2026. Overall hormone therapy use nearly doubled, from about 1.7% to 3.6%, with women aged 45–54 driving the steepest rise.

Broken down by route of administration, vaginal products moved from about 0.45% to 1.26% of women in outpatient care — a near-tripling, and one of the two fastest-growing categories in the entire dataset alongside transdermal patches and gels. Both outpaced oral tablets and injectables by a wide margin.

That distinction matters more than it might look. Vaginal estrogen is not a lower dose of the same treatment as an oral pill or a patch. It’s a different treatment, delivered locally to the tissue that needs it, with a systemic absorption profile low enough that it is generally treated as a separate clinical decision from systemic hormone therapy — one a woman can often make even if she isn’t a candidate for, or doesn’t want, HRT more broadly. The prescribing data rising this fast, on a treatment this specific, means a genuinely large number of clinicians and patients are having a conversation that, for most of the last two decades, mostly didn’t happen.

---

What Genitourinary Syndrome of Menopause Actually Is

GSM is the current clinical name — replacing the older, blunter “vaginal atrophy” — for the changes that happen across the vulva, vagina, bladder and urethra as estrogen availability falls. All of that tissue carries estrogen receptors, which is why the symptoms cluster the way they do: vaginal dryness and burning, pain or discomfort during sex, and a set of urinary symptoms — urgency, frequency, and recurrent infections — that seem unrelated to the vaginal symptoms but come from the exact same underlying cause.

A 2026 clinical review in the Journal of Women’s Health puts the prevalence at somewhere between 27% and 84% of postmenopausal individuals, depending on the population studied — a wide range, but even the low end describes a common condition, and the true figure is almost certainly pushed down by underreporting rather than up by overdiagnosis. The British Menopause Society’s 2026 consensus statement calls GSM a “silent epidemic,” and names the specific mechanism behind the silence: symptoms often don’t become noticeable until years after the hormonal shift that caused them, by which point the connection to menopause has been lost entirely. A woman dealing with recurrent UTIs at 48 is unlikely to connect them to the same hormonal transition producing her hot flashes and sleep problems, because nothing about the timing tells her they’re related.

That delay is also why GSM sits oddly across the perimenopause/menopause line in most of the research. The large prevalence studies are almost all conducted in postmenopausal women, and a lot of the clinical literature — including a 2025 meta-analysis comparing CO2 laser therapy with vaginal estrogen — is carried out in women with an average age in their late fifties, despite “perimenopause” sometimes appearing in the title. The same evidence gap that shows up everywhere else in menopause research — trials built on women well past the transition, applied to women in the middle of it — applies here too. What’s known with more confidence is the biology: estrogen decline is already underway well before periods stop, and for some women the tissue effects start showing up in the same years as irregular cycles and early hot flashes, not years afterward.

---

Why So Few Women Bring It Up

A 2026 qualitative study in the International Urogynecology Journal interviewed women who had actually been prescribed vaginal estrogen — women already past the first hurdle of raising it — and still found real barriers to using it consistently. The themes that came up most: confusion about exactly what vaginal estrogen treats and how it differs from systemic HRT, cost and insurance coverage, and — the one worth sitting with — concern about cancer risk. Every one of those barriers eased once a clinician actually explained the difference between a locally-acting, low-absorption treatment and a systemic one. The problem wasn’t the treatment. It was that nobody had walked them through what it actually does.

That confusion runs in both directions. Some women avoid raising vaginal symptoms at all because they assume the only fix is systemic hormone therapy, and they’ve already decided that isn’t for them — sometimes for good clinical reasons, sometimes out of an outdated sense of what “being on hormones” means. Others are on systemic HRT already and don’t realize it doesn’t reliably resolve vaginal and urinary symptoms on its own, so they stop mentioning symptoms that are, in fact, still there and still treatable.

And there’s a simpler barrier underneath all of it: these are symptoms that feel private in a way hot flashes don’t. A hot flash happens in front of other people. Vaginal dryness and painful sex happen nowhere anyone else can see them, which makes them easy to carry alone and easy to assume are unusual, even though the prevalence data says the opposite.

---

What the Evidence Actually Says About Treatment

Low-dose vaginal estrogen — creams, tablets, rings, applied locally — is the best-studied treatment for GSM and is described in current guidelines as first-line therapy. Because it acts on the tissue directly rather than circulating systemically at meaningful levels, its risk profile is genuinely different from oral or transdermal systemic hormone therapy, which is precisely the distinction the barriers study above found so many women had never been told. Whether it’s appropriate for a given woman — including anyone with a personal history of hormone-sensitive cancer — is a decision that depends on individual history and belongs with a clinician who has the full picture, not a blog post. But “vaginal estrogen carries the same considerations as systemic HRT” is not an accurate starting assumption, and starting from an inaccurate assumption is exactly what keeps a treatable symptom untreated.

For milder symptoms, or for women who prefer not to use hormonal treatment at all, non-hormonal vaginal moisturizers and lubricants are a reasonable first step and help many women adequately on their own. For those exploring alternatives to hormonal treatment specifically, fractional CO2 laser therapy is a newer, non-hormonal option under active study; a 2025 systematic review and meta-analysis found no statistically significant difference between CO2 laser and vaginal estrogen across most measured outcomes, which suggests it may be a genuine alternative for some women — though the evidence base is smaller and newer than the decades of data behind vaginal estrogen, and it’s worth discussing with a clinician as one option among several rather than a default.

None of this is a recommendation for what any individual woman should do. It’s an argument for treating GSM as a normal, common, and usually solvable part of the transition — worth a specific conversation, not a symptom to fold silently into “getting older.”

---

The practical difficulty is rarely the medicine. It’s that these symptoms tend to sit outside whatever a woman is already tracking — the sleep, the cycle, the hot flashes — because they feel like their own separate, private problem rather than part of the same pattern. PeriFlow’s symptom tracking already includes vaginal dryness, urinary symptoms and libido changes alongside the more commonly discussed ones, precisely because leaving them off the list is part of how they end up unmentioned to a doctor, too.

Try PeriFlow free for 7 days Track what’s actually happening — including the symptoms that are hardest to bring up — against where you are in your cycle.

Many women who eventually raise GSM with a clinician describe the same thing afterward: relief that it had a name, and mild frustration that nobody mentioned it sooner. The data suggests that conversation is finally becoming more common. It doesn’t have to wait for a study to reach you first.

---

Suggested internal links: HRT Prescriptions for Women 45–54 Have Nearly Tripled · What to Bring to Your Perimenopause Appointment · Perimenopause Symptoms